Dr. Martin Kankam

Internal Medicine
Kansas City VAMC
4101 S 4th St, 
Leavenworth, KS 
Kansas City VAMC
4101 S 4th St, 
Leavenworth, KS 

Overview

Martin Kankam is a primary care provider, practicing in Internal Medicine in Leavenworth, Kansas.

His clinical expertise encompasses Gout, Hepatitis A, Headache, and Obesity.

He is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 7 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in KS

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Kansas City VAMC
4101 S 4th St, Leavenworth, KS 66048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder
A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
Enrollment Status: Completed
Publish Date: April 16, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers
Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers
Enrollment Status: Completed
Publish Date: July 11, 2023
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Randomized, Single-dose, Two-period, Two-treatment (Fed vs Fasted), Two-sequence, Crossover Study in Healthy Adult Subjects to Assess the Effect of Food on the Absorption and Bioavailability of CTx-1301 (Dexmethylphenidate)
An Open-label, Randomized, Single-dose, Two-period, Two-treatment (Fed vs Fasted), Two-sequence, Crossover Study in Healthy Adult Subjects to Assess the Effect of Food on the Absorption and Bioavailability of CTx-1301 (Dexmethylphenidate)
Enrollment Status: Completed
Publish Date: October 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 in Healthy Subjects
Enrollment Status: Completed
Publish Date: July 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

25 Total Publications

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans.
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans.
Journal: Molecular metabolism
Published: February 10, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Patrick M. Moriarty
Internal Medicine
Expertise in
13
conditions
Dr. Patrick M. Moriarty
Internal Medicine

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (22.0 miles away)
913-588-1227
Experience:
42+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Moriarty is a primary care provider, practicing in Internal Medicine in Kansas City, Kansas. He has been practicing medicine for over 42 years. Dr. Moriarty is highly rated in 13 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), and Defective Apolipoprotein B-100. Dr. Moriarty is currently accepting new patients.

Expertise in
12
conditions
Dr. Albert I. Ko
Internal Medicine
Expertise in
12
conditions
Dr. Albert I. Ko
Internal Medicine
3901 Rainbow Blvd # Ms 2027, 
Kansas City, KS 
 (18.5 miles away)
913-588-1227
Languages Spoken:
English

Albert Ko is a primary care provider, practicing in Internal Medicine in Kansas City, Kansas. Dr. Ko is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Leptospirosis, Zika Virus Disease, COVID-19, and Achalasia Microcephaly Syndrome.

Expertise in
75
conditions
Dr. Vikas Agarwal
Internal Medicine
Expertise in
75
conditions
Dr. Vikas Agarwal
Internal Medicine

Mosaic Life Care At St. Joseph-Internal Medicine Plaza 2

901 Heartland Rd Ste 3800, 
Saint Joseph, MO 
 (35.7 miles away)
816-671-4800
Languages Spoken:
English
See accepted insurances

Vikas Agarwal is a primary care provider, practicing in Internal Medicine in Saint Joseph, Missouri. Dr. Agarwal is highly rated in 75 conditions, according to our data. His clinical expertise encompasses Myositis, COVID-19, Takayasu Arteritis, Kidney Transplant, and Vertebroplasty.

Frequently Asked Questions about Dr. Martin Kankam

How do I make an appointment with Dr. Martin Kankam?

You can book an appointment with Dr. Martin Kankam by calling their office at 913-682-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Martin Kankam a top-rated expert for Gout?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Martin Kankam is classified as an Experienced expert for Gout, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Martin Kankam specialize in?

While Dr. Martin Kankam is a Internal Medicine, they have specific expertise in Gout, Hepatitis A, and Headache. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Martin Kankam participate in research or clinical trials?

Yes. Dr. Martin Kankam has published 25 articles and abstracts on conditions like Gout. You can view a list of Dr. Martin Kankam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Martin Kankam accept my insurance?

Dr. Martin Kankam accepts most major insurance plans, including Blue Cross Blue Shield and UnitedHealthcare. We recommend calling the office directly at 913-682-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kankam's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile